AI Article Synopsis
Article Abstract
Immune-mediated colitis is an uncommon but well-documented adverse event in patients receiving nivolumab or ipilimumab therapy. In this report, we present a 69-year-old man who developed severe hypokalemia and colitis with significant corrected Q-T segment (QTc) prolongation as a result of combination nivolumab-ipilimumab immunotherapy for clear cell renal cell carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948332 | PMC |
| http://dx.doi.org/10.1155/2019/7896749 | DOI Listing |
Publication Analysis
Top Keywords
severe hypokalemia
8
qtc prolongation
8
ipilimumab- nivolumab-induced
4
nivolumab-induced colitis
4
colitis causing
4
causing severe
4
hypokalemia qtc
4
prolongation immune-mediated
4
immune-mediated colitis
4
colitis uncommon
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!